Biosight Granted Orphan Drug Designation from the FDA for Aspacytarabine for the Treatment of Myelodysplastic Syndromes
AIRPORT CITY, Israel, Aug. 1, 2022 /PRNewswire/ -- Biosight Ltd ., a pharmaceutical development company focused on the development of innovative therapeutics for hematological malignancies and disorder, announced today that theUnited States Food & Drug Administration(FDA) has granted Orphan Drug Designation to aspacytarabine (BST-236), an investigational novel antimetabolite, for the treatment of myelodysplastic syndromes, in addition to the Orphan Drug Designation granted in 2019 for aspacytarabine for the treatment of acute myeloid leukemia (AML).